CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0065 (clinicaltrials.gov NCT No: NCT01169636)
Title:Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by A Randomized Phase-II Study of ICE compared with Panobinostat Plus ICE For Patients With Relapsed and refractory Classical Hodgkin Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:Carboplatin; Etoposide; Ifosfamide; LBH589 "B" (oral) ; Panobinostat
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of the drugs ifosfamide, carboplatin, and etoposide (a
routine chemotherapy called ICE) and panobinostat and that can be given to
patients with relapsed or refractory Hodgkin's lymphoma.

The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Carboplatin
Etoposide
Ifosfamide
LBH589 "B" (oral)
Panobinostat
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults